Monotropein isolated from the roots of Morinda officinalis ameliorates proinflammatory mediators in RAW 264.7 macrophages and dextran sulfate sodium (DSS)-induced colitis via NF-κB inactivation

Food and Chemical Toxicology

Volumn 53, Issue , 2013, Pages 263-271

  Shin, Ji Sun ^a,b   Yun, Kyung Jin ^a   Chung, Kyung Sook ^a   Seo, Kyeong Hwa ^a   Park, Hee Juhn ^c   Cho, Young Wuk ^b   Baek, Nam In ^a   Jang, DaeSik ^a   Lee, Kyung Tae ^a  

^a Kyung Hee University   (South Korea)

^b Kyung Hee University Hospital   (South Korea)

^c Sangji University   (South Korea)

Author keywords

Monotropein; Morinda officinalis; Nuclear factor B; Ulcerative colitis

Indexed keywords

ANTIINFLAMMATORY AGENT; CYCLOOXYGENASE 2; DEXTRAN SULFATE; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; MESSENGER RNA; MONOTROPEIN; MYELOPEROXIDASE; ROSIGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; COLITIS; COLON MUCOSA; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE MODEL; DRUG ISOLATION; DRUG SCREENING; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; INFLAMMATION; MACROPHAGE; MALE; MORINDA OFFICINALIS; MOUSE; NONHUMAN; PLANT ROOT; PROTEIN DEGRADATION; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CELL LINE, TUMOR; COLITIS; CYCLOOXYGENASE 2; DEXTRAN SULFATE; I-KAPPA B PROTEINS; INFLAMMATION MEDIATORS; INTERLEUKIN-1BETA; IRIDOIDS; LIPOPOLYSACCHARIDES; MACROPHAGES; MICE; MORINDA; NF-KAPPA B; NITRIC OXIDE SYNTHASE TYPE II; PEROXIDASE; PHOSPHORYLATION; PLANT ROOTS; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA;

MORINDA OFFICINALIS; RUBIACEAE;

EID: 84872196588     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2012.12.013     Document Type: Article

References (54)

1. An H.J., Kim I.T., Park H.J., Kim H.M., Choi J.H., Lee K.T. Tormentic acid, a triterpenoid saponin, isolated from Rosa rugosa, inhibited LPS-induced iNOS, COX-2, and TNF-alpha expression through inactivation of the nuclear factor-kappab pathway in RAW 264.7 macrophages. Int. Immunopharmacol. 2011, 11:504-510.
2. Atreya I., Atreya R., Neurath M.F. NF-kappaB in inflammatory bowel disease. J. Intern. Med. 2008, 263:591-596.
3. Auphan N., DiDonato J.A., Rosette C., Helmberg A., Karin M. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 1995, 270:286-290.
4. Bao L., Qin L., Liu L., Wu Y., Han T., Xue L., Zhang Q. Anthraquinone compounds from Morinda officinalis inhibit osteoclastic bone resorption in vitro. Chem. Biol. Interact. 2011, 194:97-105.
5. Baumgart D.C., Carding S.R. Inflammatory bowel disease: cause and immunobiology. Lancet 2007, 369:1627-1640.
6. Bonizzi G., Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol. 2004, 25:280-288.
7. Boughton-Smith N.K. Pathological and therapeutic implications for nitric oxide in inflammatory bowel disease. J. R. Soc. Med. 1994, 87:312-314.
8. Chandrakesan P., Ahmed I., Chinthalapally A., Singh P., Awasthi S., Anant S., Umar S. Distinct compartmentalization of NF-kappaB activity in crypt and crypt-denuded lamina propria precedes and accompanies hyperplasia and/or colitis following bacterial infection. Infect. Immun. 2012, 80:753-767.
9. Choi J., Lee K.T., Choi M.Y., Nam J.H., Jung H.J., Park S.K., Park H.J. Antinociceptive anti-inflammatory effect of Monotropein isolated from the root of Morinda officinalis. Biol. Pharm. Bull. 2005, 28:1915-1918.
10. Cimanga K., Hermans N., Apers S., Van Miert S., Van den Heuvel H., Claeys M., Pieters L., Vlietinck A. Complement-inhibiting iridoids from Morinda morindoides. J. Nat. Prod. 2003, 66:97-102.
11. Clafshenkel W.P., King T.L., Kotlarczyk M.P., Cline J.M., Foster W.G., Davis V.L., Witt-Enderby P.A. Morinda citrifolia (Noni) juice augments mammary gland differentiation and reduces mammary tumor growth in mice expressing the unactivated c-erbB2 Transgene. Evid Based Complement Alternat Med 2012, 2012:487423.
12. Craig R., Larkin A., Mingo A.M., Thuerauf D.J., Andrews C., McDonough P.M., Glembotski C.C. P38 MAPK and NF-kappa B collaborate to induce interleukin-6 gene expression and release. Evidence for a cytoprotective autocrine signaling pathway in a cardiac myocyte model system. J. Biol. Chem. 2000, 275:23814-23824.
13. Cross R.K., Wilson K.T. Nitric oxide in inflammatory bowel disease. Inflamm. Bowel Dis. 2003, 9:179-189.
14. Dong W.G., Liu S.P., Yu B.P., Wu D.F., Luo H.S., Yu J.P. Ameliorative effects of sodium ferulate on experimental colitis and their mechanisms in rats. World J. Gastroenterol. 2003, 9:2533-2538.
15. El-Naggar L.J., Beal J.L. Iridoids. A review. J. Nat. Prod. 1980, 43:649-707.
16. Elson C.O., Cong Y., McCracken V.J., Dimmitt R.A., Lorenz R.G., Weaver C.T. Experimental models of inflammatory bowel disease reveal innate, adaptive, and regulatory mechanisms of host dialogue with the microbiota. Immunol. Rev. 2005, 206:260-276.
17. Ghosh S., Karin M. Missing pieces in the NF-kappaB puzzle. Cell 2002, 109(Suppl.):S81-S96.
18. Guslandi M. Nitric oxide and inflammatory bowel diseases. Eur. J. Clin. Invest. 1998, 28:904-907.
19. Hanauer S.B. Inflammatory bowel disease. N. Engl. J. Med. 1996, 334:841-848.
20. Hanauer S.B. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm. Bowel Dis. 2006, 12(Suppl. 1):S3-S9.
21. Hibi T., Inoue N., Ogata H., Naganuma M. Introduction and overview: recent advances in the immunotherapy of inflammatory bowel disease. J. Gastroenterol. 2003, 38(Suppl. 15):36-42.
22. Islam M.S., Murata T., Fujisawa M., Nagasaka R., Ushio H., Bari A.M., Hori M., Ozaki H. Anti-inflammatory effects of phytosteryl ferulates in colitis induced by dextran sulphate sodium in mice. Br. J. Pharmacol. 2008, 154:812-824.
23. Karin M., Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu. Rev. Immunol. 2000, 18:621-663.
24. Kim I.T., Park H.J., Nam J.H., Park Y.M., Won J.H., Choi J., Choe B.K., Lee K.T. In vitro and in vivo anti-inflammatory and antinociceptive effects of the methanol extract of the roots of Morinda officinalis. J. Pharm. Pharmacol. 2005, 57:607-615.
25. Kim J.M., Kang H.W., Cha M.Y., Yoo D., Kim N., Kim I.K., Ku J., Kim S., Ma S.H., Jung H.C., Song I.S., Kim J.S. Novel guggulsterone derivative GG-52 inhibits NF-kappaB signaling in intestinal epithelial cells and attenuates acute murine colitis. Lab. Invest. 2010, 90:1004-1015.
26. Kitajima S., Takuma S., Morimoto M. Changes in colonic mucosal permeability in mouse colitis induced with dextran sulfate sodium. Exp. Anim. 1999, 48:137-143.
27. Krieglstein C.F., Cerwinka W.H., Laroux F.S., Salter J.W., Russell J.M., Schuermann G., Grisham M.B., Ross C.R., Granger D.N. Regulation of murine intestinal inflammation by reactive metabolites of oxygen and nitrogen: divergent roles of superoxide and nitric oxide. J. Exp. Med. 2001, 194:1207-1218.
28. Lee S.J., Lim K.T. Glycoprotein isolated from Ulmus davidiana Nakai regulates expression of iNOS and COX-2 in vivo and in vitro. Food Chem. Toxicol. 2007, 45:990-1000.
29. Lorenz R.G., McCracken V.J., Elson C.O. Animal models of intestinal inflammation: ineffective communication between coalition members. Springer Semin. Immunopathol. 2005, 27:233-247.
30. Malle E., Furtmuller P.G., Sattler W., Obinger C. Myeloperoxidase: a target for new drug development?. Br. J. Pharmacol. 2007, 152:838-854.
31. Mohanty P., Aljada A., Ghanim H., Hofmeyer D., Tripathy D., Syed T., Al-Haddad W., Dhindsa S., Dandona P. Evidence for a potent antiinflammatory effect of rosiglitazone. J. Clin. Endocrinol. Metab. 2004, 89:2728-2735.
32. Netea M.G., van der Meer J.W., van Deuren M., Kullberg B.J. Proinflammatory cytokines and sepsis syndrome: not enough, or too much of a good thing?. Trends Immunol. 2003, 24:254-258.
33. Okayasu I., Hatakeyama S., Yamada M., Ohkusa T., Inagaki Y., Nakaya R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 1990, 98:694-702.
34. Onizawa M., Nagaishi T., Kanai T., Nagano K., Oshima S., Nemoto Y., Yoshioka A., Totsuka T., Okamoto R., Nakamura T., Sakamoto N., Tsuchiya K., Aoki K., Ohya K., Yagita H., Watanabe M. Signaling pathway via TNF-alpha/NF-kappaB in intestinal epithelial cells may be directly involved in colitis-associated carcinogenesis. Am. J. Physiol. Gastrointest. Liver Physiol. 2009, 296:G850-G859.
35. Owczarek D., Cibor D., Szczepanek M., Mach T. Biological therapy of inflammatory bowel disease. Pol. Arch. Med. Wewn. 2009, 119:84-88.
36. Perkins N.D. Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat. Rev. Mol. Cell Biol. 2007, 8:49-62.
37. Peyrin-Biroulet L., Desreumaux P., Sandborn W.J., Colombel J.F. Crohn's disease: beyond antagonists of tumour necrosis factor. Lancet 2008, 372:67-81.
38. Rahman F.Z., Smith A.M., Hayee B., Marks D.J., Bloom S.L., Segal A.W. Delayed resolution of acute inflammation in ulcerative colitis is associated with elevated cytokine release downstream of TLR4. PLoS One 2010, 5:e9891.
39. Rath H.C., Schultz M., Freitag R., Dieleman L.A., Li F., Linde H.J., Scholmerich J., Sartor R.B. Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice. Infect. Immun. 2001, 69:2277-2285.
40. Sanchez-Hidalgo M., Martin A.R., Villegas I., Alarcon De La Lastra C. Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, reduces chronic colonic inflammation in rats. Biochem. Pharmacol. 2005, 69:1733-1744.
41. Sanchez-Hidalgo M., Martin A.R., Villegas I., de la Lastra C.A. Rosiglitazone, a PPARgamma ligand, modulates signal transduction pathways during the development of acute TNBS-induced colitis in rats. Eur. J. Pharmacol. 2007, 562:247-258.
42. Sanchez-Munoz F., Dominguez-Lopez A., Yamamoto-Furusho J.K. Role of cytokines in inflammatory bowel disease. World J. Gastroenterol. 2008, 14:4280-4288.
43. Sasaki M., Bharwani S., Jordan P., Joh T., Manas K., Warren A., Harada H., Carter P., Elrod J.W., Wolcott M., Grisham M.B., Alexander J.S. The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor pravastatin reduces disease activity and inflammation in dextran-sulfate induced colitis. J. Pharmacol. Exp. Ther. 2003, 305:78-85.
44. Scheinecker C., Redlich K., Smolen J.S. Cytokines as therapeutic targets: advances and limitations. Immunity 2008, 28:440-444.
45. Shibata W., Maeda S., Hikiba Y., Yanai A., Ohmae T., Sakamoto K., Nakagawa H., Ogura K., Omata M. Cutting edge: the IkappaB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks inflammatory injury in murine colitis. J. Immunol. 2007, 179:2681-2685.
46. Shin J.S., Park Y.M., Choi J.H., Park H.J., Shin M.C., Lee Y.S., Lee K.T. Sulfuretin isolated from heartwood of Rhus verniciflua inhibits LPS-induced inducible nitric oxide synthase, cyclooxygenase-2, and pro-inflammatory cytokines expression via the down-regulation of NF-kappaB in RAW 264.7 murine macrophage cells. Int. Immunopharmacol. 2010, 10:943-950.
47. Shin J.S., Yun C.H., Cho Y.W., Baek N.I., Choi M.S., Jeong T.S., Chung H.G., Lee K.T. Indole-containing fractions of Brassica rapa inhibit inducible nitric oxide synthase and pro-inflammatory cytokine expression by inactivating nuclear factor-kappaB. J. Med. Food 2011, 14:1527-1537.
48. Villasenor I.M. Bioactivities of Iridoids. Anti-Inflammatory Anti-Allergy Agents Med. Chem. 2007, 6:307-314.
49. Wirtz S., Neurath M.F. Mouse models of inflammatory bowel disease. Adv. Drug Delivery Rev. 2007, 59:1073-1083.
50. Xu C.T., Meng S.Y., Pan B.R. Drug therapy for ulcerative colitis. World J. Gastroenterol. 2004, 10:2311-2317.
51. Yamamoto Y., Gaynor R.B. Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J. Clin. Invest. 2001, 107:135-142.
52. Yamamoto Y., Gaynor R.B. IkappaB kinases: key regulators of the NF-kappaB pathway. Trends Biochem. Sci. 2004, 29:72-79.
53. Yin M.J., Yamamoto Y., Gaynor R.B. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 1998, 396:77-80.
54. Yu T., Shim J., Yang Y., Byeon S.E., Kim J.H., Rho H.S., Park H., Sung G.H., Kim T.W., Rhee M.H., Cho J.Y. 3-(4-(tert-Octyl)phenoxy)propane-1,2-diol suppresses inflammatory responses via inhibition of multiple kinases. Biochem. Pharmacol. 2012, 83:1540-1551.